Kaddouri Halima, Nakache Serge, Houzé Sandrine, Mentré France, Le Bras Jacques
Centre National de Référence du Paludisme, Laboratoire de Parasitologie, Hôpital Bichat-Claude Bernard and Université René Descartes, Paris, France.
Antimicrob Agents Chemother. 2006 Oct;50(10):3343-9. doi: 10.1128/AAC.00367-06.
The extension of drug resistance among malaria-causing Plasmodium falciparum parasites in Africa necessitates implementation of new combined therapeutic strategies. Drug susceptibility phenotyping requires precise measurements. Until recently, schizont maturation and isotopic in vitro assays were the only methods available, but their use was limited by technical constraints. This explains the revived interest in the development of replacement methods, such as the Plasmodium lactate dehydrogenase (pLDH) immunodetection assay. We evaluated a commercially controlled pLDH enzyme-linked immunosorbent assay (ELISA; the ELISA-Malaria antigen test; DiaMed AG, Cressier s/Morat, Switzerland) to assess drug susceptibility in a standard in vitro assay using fairly basic laboratory equipment to study the in vitro resistance of malaria parasites to major antimalarials. Five Plasmodium falciparum clones and 121 clinical African isolates collected during 2003 and 2004 were studied by the pLDH ELISA and the [8-(3)H]hypoxanthine isotopic assay as a reference with four antimalarials. Nonlinear regression with a maximum effect model was used to estimate the 50% inhibitory concentration (IC(50)) and its confidence intervals. The two methods were observed to have similar reproducibilities, but the pLDH ELISA demonstrated a higher sensitivity. The high correlation (r = 0.98) and the high phenotypic agreement (kappa = 0.88) between the two methods allowed comparison by determination of the IC(50)s. Recently collected Plasmodium falciparum African isolates were tested by pLDH ELISA and showed drug resistance or decreased susceptibilities of 62% to chloroquine and 11.5% to the active metabolite of amodiaquine. No decreased susceptibility to lumefantrine or the active metabolite of artemisinin was detected. The availability of this simple and highly sensitive pLDH immunodetection assay will provide an easier method for drug susceptibility testing of malaria parasites.
非洲导致疟疾的恶性疟原虫寄生虫耐药性的扩展使得实施新的联合治疗策略成为必要。药物敏感性表型分析需要精确测量。直到最近,裂殖体成熟和同位素体外测定法是仅有的可用方法,但它们的使用受到技术限制。这就解释了为何人们对开发替代方法重新产生兴趣,比如疟原虫乳酸脱氢酶(pLDH)免疫检测测定法。我们评估了一种商业控制的pLDH酶联免疫吸附测定法(ELISA;疟疾抗原检测ELISA;DiaMed AG,瑞士克雷西耶/莫拉特),以在使用相当基础的实验室设备的标准体外测定法中评估药物敏感性,来研究疟原虫对主要抗疟药的体外耐药性。使用五个恶性疟原虫克隆和2003年至2004年期间收集的121份非洲临床分离株,通过pLDH ELISA和作为参考的[8-(3)H]次黄嘌呤同位素测定法对四种抗疟药进行了研究。使用最大效应模型的非线性回归来估计50%抑制浓度(IC(50))及其置信区间。观察到这两种方法具有相似的重现性,但pLDH ELISA表现出更高的灵敏度。两种方法之间的高相关性(r = 0.98)和高表型一致性(kappa = 0.88)使得可以通过测定IC(50)进行比较。最近收集的非洲恶性疟原虫分离株通过pLDH ELISA进行检测,结果显示对氯喹的耐药性或敏感性降低的比例为62%,对阿莫地喹活性代谢物的为11.5%。未检测到对卤泛群或青蒿素活性代谢物的敏感性降低。这种简单且高度灵敏的pLDH免疫检测测定法的可用性将为疟原虫的药物敏感性测试提供一种更简便的方法。